These therapies have been designed to selectively target airway eosinophils, using peripheral blood eosinophil count as a surrogate marker of airway eosinophilia with the assumption that IL-5 mediates its effects via IL-5R found primarily on the surface of eosinophils. This evidence concerns the gene IL5 and Increased total eosinophil count.